Posted On: 05/10/2016 2:53:57 PM
Post# of 72443
The past is not always a prediction of the future, but after looking at ctix last quarterly report, there was a pr on each day following
Wednesday, February 10, 2016
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian CancerMarketwired (Wed, Feb 10)
Tuesday, February 9, 2016
Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of Antibiotic Brilacidin for ABSSSIMarketwired (Tue, Feb 9)
Monday, February 8, 2016
CELLCEUTIX CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online (Mon, Feb
Wednesday, February 10, 2016
Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian CancerMarketwired (Wed, Feb 10)
Tuesday, February 9, 2016
Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of Antibiotic Brilacidin for ABSSSIMarketwired (Tue, Feb 9)
Monday, February 8, 2016
CELLCEUTIX CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online (Mon, Feb
(0)
(0)Scroll down for more posts ▼
